The pooled prevalence of chronic painful neuropathy is 41.22% among individuals with chemotherapy-induced peripheral neuropathy (CIPN).
Patients treated with platinum-based agents and taxanes had the highest prevalence of chronic painful chemotherapy-induced peripheral neuropathy, researchers found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback